Phase1a, Dose-escalation Study of NNI-362 in Healthy Aged Volunteers

NCT04074837 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

56

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer Disease

Interventions

DRUG: NNI-362
DRUG: Placebo

Sponsor

Neuronascent, Inc.

Collaborators

[object Object]